CYP2A6 activity and cigarette consumption interact in smoking-related lung cancer susceptibility.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
20 Dec 2023
Historique:
accepted: 14 12 2023
received: 22 03 2023
revised: 28 07 2023
medline: 20 12 2023
pubmed: 20 12 2023
entrez: 20 12 2023
Statut: aheadofprint

Résumé

Cigarette smoke, containing both nicotine and carcinogens, causes lung cancer. However, not all smokers develop lung cancer, highlighting the importance of the interaction between host susceptibility and environmental exposure in tumorigenesis. Here, we aimed to delineate the interaction between metabolizing ability of tobacco carcinogens and smoking intensity in mediating genetic susceptibility to smoking-related lung tumorigenesis. Single-variant and gene-based associations of 43 tobacco carcinogen-metabolizing genes with lung cancer were analyzed using summary statistics and individual-level genetic data, followed by causal inference of Mendelian randomization, mediation analysis, and structural equation modeling. Cigarette smoke-exposed cell models were used to detect gene expression patterns in relation to specific alleles. Data from the International Lung Cancer Consortium (29,266 cases and 56,450 controls) and UK Biobank (2,155 cases and 376,329 controls) indicated that the genetic variant rs56113850 C>T located in intron 4 of CYP2A6 was significantly associated with decreased lung cancer risk among smokers [odds ratio (OR) = 0.88, 95% confidence interval = 0.85-0.91, P = 2.18×10-16], which might interact (Pinteraction = 0.028) with and partially be mediated (ORindirect = 0.987) by smoking status. Smoking intensity accounted for 82.3% of the effect of CYP2A6 activity on lung cancer risk but entirely mediated the genetic effect of rs56113850. Mechanistically, the rs56113850 T allele rescued the downregulation of CYP2A6 caused by cigarette smoke exposure, potentially through preferential recruitment of transcription factor HLTF. Together, this study provides additional insights into the interplay between host susceptibility and carcinogen exposure in smoking-related lung tumorigenesis.

Identifiants

pubmed: 38117513
pii: 731786
doi: 10.1158/0008-5472.CAN-23-0900
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Mulong Du (M)

Harvard University, Boston, United States.

Junyi Xin (J)

Nanjing Medical University, Nanjing, China.

Rui Zheng (R)

Nanjing Medical University, China.

Qianyu Yuan (Q)

Harvard T.H. Chan School of Public Health, Boston, MA, United States.

Zhihui Wang (Z)

Harvard School of Public Health, Boston, MA, United States.

Hongliang Liu (H)

Duke University School of Medicine, Durham, NC, United States.

Hanting Liu (H)

Nanjing Medical University, Nanjing, China.

Guoshuai Cai (G)

University of South Carolina, Columbia, United States.

Demetrius Albanes (D)

National Cancer Institute, Bethesda, MD, United States.

Stephen Lam (S)

British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Adonina Tardon (A)

Universidad de Oviedo, Public Health Department, Oviedo, Asturias, Spain.

Chu Chen (C)

Fred Hutchinson Cancer Center, Seattle, WA, United States.

Stig E Bojesen (SE)

Copenhagen University Hospital and University of Copenhagen, Herlev, Denmark.

Maria Teresa Landi (MT)

National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, United States.

Mattias Johansson (M)

International Agency For Research On Cancer, Lyon, France.

Angela Risch (A)

University of Salzburg, Salzburg, Austria.

Heike Bickeböller (H)

University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.

H-Erich Wichmann (HE)

Institute of Epidemiology, Germany.

Gad Rennert (G)

Carmel Medical Center, Haifa, Israel.

Susanne Arnold (S)

University of Kentucky, Lexington, KY, United States.

Paul Brennan (P)

International Agency For Research On Cancer, Lyon, France.

John K Field (JK)

University of Liverpool, Liverpool UK, United Kingdom.

Sanjay S Shete (SS)

The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Loïc Le Marchand (L)

University of Hawaii Cancer Center, Honolulu, Hawaii, United States.

Geoffrey Liu (G)

Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Angeline S Andrew (AS)

Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.

Lambertus A Kiemeney (LA)

Radboud University Medical Centre, Nijmegen, Netherlands.

Shanbeh Zienolddiny (S)

National Institute of Occupational Health, Oslo, Oslo, Norway.

Kjell Grankvist (K)

Umeå University, Umea, Sweden.

Mikael Johansson (M)

Umeå University, Umea, Sweden.

Neil E Caporaso (NE)

National Cancer Institute, Rockville, MD, United States.

Angela Cox (A)

University of Sheffield, Sheffield, United Kingdom.

Yun-Chul Hong (YC)

Seoul National University College of Medicine, Seoul, Korea (South), Republic of.

Jian-Min Yuan (JM)

UPMC Hillman Cancer Center, Pittsburgh, PA, United States.

Matthew B Schabath (MB)

H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.

Melinda C Aldrich (MC)

Vanderbilt University Medical Center, Nashville, United States.

Meilin Wang (M)

Nanjing Medical University, Nanjing, China.

Hongbing Shen (H)

Nanjing Medical University, Nanjing, jiangsu, China.

Feng Chen (F)

School of Public Health (SPH), Nanjing Medical University, Nanjing, Jiangsu, China.

Zhengdong Zhang (Z)

Nanjing Medical University, Nanjing, China.

Rayjean J Hung (RJ)

Sinai Health System, Toronto, Canada.

Christopher I Amos (CI)

Baylor College of Medicine, Houston, TX, United States.

Qingyi Wei (Q)

Duke University Medical Center, Durham, NC, United States.

Philip Lazarus (P)

College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, United States.

David C Christiani (DC)

Harvard School of Public Health, Boston, MA, United States.

Classifications MeSH